Publications by authors named "Pisit Tangkijvanich"

Article Synopsis
  • A study evaluated the impact of specific genetic polymorphisms on the severity of fibrosis and steatosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
  • Using MRI techniques, they assessed liver conditions in 204 participants, finding that certain genotypes (specifically rs738409 and rs12216101) were significantly linked to higher levels of liver fibrosis.
  • The findings suggest that these genetic factors contribute to the progression of MASLD, highlighting the importance of genetic variants in this health issue, particularly within the Thai population.
View Article and Find Full Text PDF
Article Synopsis
  • The Elecsys HCV Duo immunoassay can detect both antibodies to hepatitis C virus and HCV core antigen, showing strong diagnostic performance in blood donors.
  • The study involved blood samples from 100 healthy controls and 200 HCV-infected patients, assessing the assay's ability to diagnose active HCV infection and evaluate response to treatment with direct-acting antivirals.
  • Results indicated that the assay had high sensitivity and specificity for diagnosing HCV, with a 96.5% sustained virological response rate among treated patients, making it a useful tool for managing HCV in different populations, including those with HIV.
View Article and Find Full Text PDF
Article Synopsis
  • Chronic infection with Hepatitis B Virus (HBV) leads to weak virus-specific T cell responses, complicating viral clearance while causing significant liver inflammation due to immune responses.
  • A new assay developed for detecting HBV Capsid-Antibody Complexes (CACs) showed high accuracy in measuring these complexes in serum and linked them to increased liver inflammation and damage in chronic hepatitis B patients.
  • The study provides strong evidence that CACs play a key role in complement-mediated liver injury, establishing a new factor to consider alongside existing clinical markers for monitoring inflammation in chronic hepatitis B.
View Article and Find Full Text PDF
Article Synopsis
  • Chronic hepatitis B virus (HBV) is a significant global health concern, with existing treatments yielding low rates of HBsAg seroclearance; VIR-2218 (elebsiran) is being studied for its potential to reduce HBsAg levels.
  • This phase 2 open-label study involved participants aged 18-65 from various countries who had chronic HBV but no cirrhosis, assessing the safety and effectiveness of VIR-2218 alone and in combination with pegylated interferon-alpha-2a.
  • The study aimed to measure adverse events and clinical outcomes, including the reduction of HBsAg and long-term seroclearance rates among those receiving different treatment regimens over a period ranging from
View Article and Find Full Text PDF

: Telehealth improves access to health care and potentially leads to better clinical outcomes. However, digital competence could be an essential factor in ensuring its adoption, particularly among older adults. This study evaluated the acceptability and perception of a mobile application platform among Thai older patients with chronic diseases according to their demographics and digital skills.

View Article and Find Full Text PDF

Sofosbuvir/Velpatasvir (SOF/VEL) is a combination drug used for chronic hepatitis C (HCV) infection. However, limited information exists regarding the pharmacokinetics of SOF/VEL and its metabolites in hemodialysis patients. We conducted a prospective investigation of the pharmacokinetic parameters of SOF/VEL after a single dose of SOF/VEL (400/100 mg) on days with and without dialysis in 12 Thai hemodialysis patients with chronic HCV infection, who had been undergoing hemodialysis for a duration of 0.

View Article and Find Full Text PDF

Gut microbiota might affect the severity and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to characterize gut dysbiosis and clinical parameters regarding fibrosis stages assessed by magnetic resonance elastography. This study included 156 patients with MASLD, stratified into no/mild fibrosis (F0-F1) and moderate/severe fibrosis (F2-F4).

View Article and Find Full Text PDF

Laser-induced graphene (LIG) electrodes have become popular for electrochemical sensor fabrication due to their simplicity for batch production without the use of reagents. The high surface area and favorable electrocatalytic properties also enable the design of small electrochemical devices while retaining the desired electrochemical performance. In this work, we systematically investigated the effect of LIG working electrode size, from 0.

View Article and Find Full Text PDF

Objectives: Criteria for antiviral treatment initiation in Thailand were complex and difficult to implement. This study determined the cost-effectiveness of 2 simplified antiviral treatment initiation criteria among patients with chronic hepatitis B in Thailand.

Methods: A hybrid model of the decision tree and Markov model was developed.

View Article and Find Full Text PDF

Long non-coding RNAs (lncRNAs), which are RNA sequences greater than 200 nucleotides in length, play a crucial role in regulating gene expression and biological processes associated with cancer development and progression. Liver cancer is a major cause of cancer-related mortality worldwide, notably in Thailand. Although machine learning has been extensively used in analyzing RNA-sequencing data for advanced knowledge, the identification of potential lncRNA biomarkers for cancer, particularly focusing on lncRNAs as molecular biomarkers in liver cancer, remains comparatively limited.

View Article and Find Full Text PDF

Activation of quiescent hepatic stellate cells (HSCs) into proliferative myofibroblasts drives extracellular cellular matrix (ECM) accumulation and liver fibrosis; nevertheless, the transcriptional network that promotes such a process is not completely understood. ZNF469 is a putative C2H2 zinc finger protein that may bind to specific genome sequences. It is found to be upregulated upon HSC activation; however, the molecular function of ZNF469 is completely unknown.

View Article and Find Full Text PDF

Background: Clinical trials have proven the efficacy and safety of atezolizumab combined with bevacizumab (A+B) in treating unresectable hepatocellular carcinoma (uHCC). This study aimed to assess the cost-utility of A+B compared to best supportive care (BSC) among uHCC patients in Thailand.

Methods: We conducted a cost-utility analysis from a societal perspective.

View Article and Find Full Text PDF

The relationship between gut dysbiosis and body mass index (BMI) in non-diabetic patients with non-alcoholic fatty liver disease (NAFLD) is not adequately characterized. This study aimed to assess gut microbiota's signature in non-diabetic individuals with NAFLD stratified by BMI. The 16S ribosomal RNA sequencing was performed for gut microbiota composition in 100 patients with NAFLD and 16 healthy individuals.

View Article and Find Full Text PDF

Altered gut microbiota has been connected to hepatocellular carcinoma (HCC) occurrence and advancement. This study was conducted to identify a gut microbiota signature in differentiating between viral-related HCC (Viral-HCC) and non-hepatitis B-, non-hepatitis C-related HCC (NBNC-HCC). Fecal specimens were obtained from 16 healthy controls, 33 patients with viral-HCC (17 and 16 cases with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, respectively), and 18 patients with NBNC-HCC.

View Article and Find Full Text PDF

Epigenetic alteration by oxidative stress is vitally involved in carcinogenesis and cancer progression. Previously, we demonstrated that oxidative stress was increased in hepatocellular carcinoma (HCC) patients and associated with tumor aggressiveness. Herein, we immunohistochemically investigated whether histone methylation, specifically H4K20me3, was upregulated in human hepatic tissues obtained from HCC patients (n = 100).

View Article and Find Full Text PDF

Extracellular vesicle-derived microRNAs (EV-miRNAs) are promising circulating biomarkers for chronic liver disease. In this study, we explored the potential significance of plasma EV-miRNAs in non-hepatitis B-, non-hepatitis C-related HCC (NBNC-HCC). We compared, using the NanoString method, plasma EV-miRNA profiles between NBNC-HCC and control groups including patients with non-alcoholic fatty liver disease (NAFLD) and healthy controls.

View Article and Find Full Text PDF

Background: Modified albumin-bilirubin (mALBI) grade has been established as a survival determinant in hepatocellular carcinoma (HCC) patients who receive locoregional and targeted therapies.

Aim: To investigate whether mALBI could predict survival in unresectable HCC (uHCC) patients who were treated with atezolizumab plus bevacizumab (AB).

Methods: A single-center, retrospective cohort study enrolled uHCC patients who received AB treatment between September 2020 and April 2023 and were followed up until June 2023.

View Article and Find Full Text PDF

Hepatitis B virus (HBV) capsid assembly modulators (CAMs) are currently being evaluated in clinical trials as potential curative therapies for HBV. This study used computational modeling to provide insights into the binding characteristics between the HBV core protein and two pyrrole-scaffold inhibitors, JNJ-6379 and GLP-26, both in the CAM-Normal (CAM-N) series. Molecular dynamics simulations showed that the pyrrole inhibitors displayed similar general binding-interaction patterns to NVR 3-778, another CAM-N, with hydrophobic interactions serving as the major driving force.

View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) is the leading cause of cancer death worldwide; nevertheless, current therapeutic options are limited or ineffective for many patients. Therefore, elucidation of molecular mechanisms in HCC biology could yield important insights for the intervention of novel therapies. Recently, various studies have reported dysregulation of long non-coding RNAs (lncRNAs) in the initiation and progression of HCC, including H19; however, the biological function of H19 in HCC remains unclear.

View Article and Find Full Text PDF

Aberrantly expressed circulating microRNAs (miRNAs) have been demonstrated to have a crucial role in the diagnosis and prognostication of various cancers, including hepatocellular carcinoma (HCC). This research aimed to examine the role of specific miRNAs in predicting the outcomes for individuals with hepatitis B virus (HBV)-related HCC treated with transarterial chemoembolization (TACE). Stored serum specimens collected prior to the first TACE procedure were employed to determine the expression of serum miR-122, miR-221, and miR-224 using quantitative real-time PCR analysis.

View Article and Find Full Text PDF

Long-term effect of Direct-acting antivirals (DAAs) on gut microbiota, short-chain fatty acids (SCFAs) and microbial translocation in patients with hepatitis C virus (HCV) infection who achieve sustained virological response (SVR) were limited. A longitudinal study of 50 patients with HCV monoinfection and 19 patients with HCV/HIV coinfection received DAAs were conducted. Fecal specimens collected at baseline and at week 72 after treatment completion (FUw72) were analyzed for 16S rRNA sequencing and the butyryl-CoA:acetateCoA transferase (BCoAT) gene expression using real-time PCR.

View Article and Find Full Text PDF

Background/aims: Ultrasonography has a low sensitivity for detecting early-stage hepatocellular carcinoma (HCC) in cirrhotic patients. Non-contrast abbreviated magnetic resonance imaging (aMRI) demonstrated a comparable performance to that of magnetic resonance imaging without the risk of contrast media exposure and at a lower cost than that of full diagnostic MRI. We aimed to investigate the cost-effectiveness of non-contrast aMRI for HCC surveillance in cirrhotic patients, using ultrasonography with alpha-fetoprotein (AFP) as a reference.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigated RG6346, a new treatment for chronic hepatitis B virus (HBV) infection, focusing on its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and patients with chronic HBV. - In the phase I trial, various dosages of RG6346 were administered, showing it was generally safe with mild side effects, while most participants experienced significant reductions in hepatitis B surface antigen (HBsAg) levels after treatment. - The results indicate RG6346 could effectively lower HBsAg and other HBV-related markers in patients, prompting further clinical development due to its promising safety profile and efficacy.
View Article and Find Full Text PDF